The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and MicroRNA 221 and 222 in prostate cancer

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1870-1875

  Lin, D ^a   Cui, F ^b   Bu, Q ^b   Yan, Chunyin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Disease Progression; Gene Expression Level; GTP Binding RAS like 3 (ARHI); MicroRNA 221 and 222; Prostate Cancer

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GUANOSINE 5' TRIPHOSPHATE BINDING RAS LIKE 3 GENE; HUMAN; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 80155161975     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900530     Document Type: Article

References (28)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 1999; 49: 8-31.
2. Seidman H, Mushinski MH, Geib SK, et al: Probabilities of eventually developing or dying of cancer-United States, 1985. CA Cancer J Clin 1985; 35: 36-56.
3. Stamey TA, Yang N, Hay AR, et al: Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.
4. Yu Y, Xu F, Peng H, et al: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999; 96: 214-219.
5. Chen Y, Zaman MS, Deng G, et al: MicroRNAs 221/222 and genistein mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011; 4: 76-86.
6. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
8. He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
9. Mraz M, Pospisilova S, Malinova K, et al: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009; 50: 506-509.
10. Strathdee G, Brown R: Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med 2002; 4: 1-17.
11. Schulz WA, Hoffmann MJ: Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 2009; 19: 172-180.
12. Schulz WA, Hatina J: Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006; 10: 100-125.
13. Li LC: Epigenetics of prostate cancer. Front Biosci 2007; 12: 3377-3397.
14. Murphy TM, Perry AS, Lawler M: The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 2008; 15: 11-25.
15. Nelson WG, De Marzo AM, Yegnasubramanian S: Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150: 3991-4002.
16. Nakayama M, Bennett CJ, Hicks JL, et al: Hypermethylation of the human glutathione Stransferase-ttgene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003; 163: 923-933.
17. Jerónimo C, Usadel H, Henrique R, et al: Quantitation of GSTP1 methylation in nonneoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93: 1747-1752.
18. Naor D, Sionov RV, Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319.
19. Woodson K, O'Reilly KJ, Ward DE, et al: CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006; 1: 183-186.
20. Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450.
21. Iorio MV, Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856.
22. Baranwal S, Alahari SK: microRNA control of tumor cell invasion and metastasis. Int J Cancer 2009; 126: 1283-1290.
23. Shi XB, Xue L, Yang J, et al: An androgenregulated microRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007; 104: 19983-19988.
24. Musiyenko A, Bitko V, Barik S: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med (Berl) 2008; 86: 313-322.
25. Lu Z, Liu M, Stribinskis V, et al: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27: 4373-4379.
26. Sun T, Wang Q, Balk S, et al: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69: 3356-3363.
27. Mercatelli N, Coppola V, Bonci D, et al: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008; 3: e4029.
28. Galardi S, Mercatelli N, Giorda E, et al: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-23724.